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etiologic agent was found, so it was considered that AA was sec-
ondary to HIV. Treatment was initiated with D4T (Stavudine),
3TC (Lamivudine) and Efavirenz achieving undetectable viral load
and increasing CD4 count. Patient also received Erythropoietin
(EPO) and granulocyte-colony stimulating factors (G-CSF) show-
ing an increased number of white blood cells (WBC) but continued
with high transfusional requeirment. We had to stop treatment in
October because of liver failure and lactic acidosis. In November
we changed Stavudine for Tenofovir and reiniciated treatment.
Viral load was always undetectable and CD4 count was  500
cells/ul. However megakaryocytopoiesis and erythropoiesis did not
respond, requiring many transfusions. Coombs Direct Test (CDT)
and Coombs Indirec Test (CIT) were positive.He showed an
immunohaematologic proﬁle with 1 autoantibody (Anti-e) and 3
alloantibodies (Anti-Jka, Anti-Lua, Anti-Cw).
As he had an identical twin, he was submitted to a syngeneic
BMT. Although he was heavily transfused (421 Units ), we did not
want to increase immunosuppression so as not to have viral reac-
tivation. The conditioning regimen consisted of Cy 50 mg/kg/qd x
4, and in order to lower the risk of engrafment failure, peripheral
blood stem cells were used to maximize the number of donor cells
infused (11  106 CD34 cells/kg). At the transplantation the
patient was in high-risk. The antiretroviral treatment was not
discontinued. No graft versus host disease (GVHD) proﬁlaxis was
needed. Neutrophils and platelets engrafted at day 11.
After 10 months of transplantation he continues in complete
haematologic remission. Serum antibodies, CDT and CIT are
negative.Viral load remains undetectable (b-DNA).
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ABSOLUTE CHIMERISM AS A TOOL IN MONITORING IMMINENT AND
MANIFEST GRAFT REJECTION AFTER HEMATOPOIETIC CELL TRANS-
PLANTATION WITH NONMYELOABLATIVE CONDITIONING
Masmas, T.N.1, Petersen, S.L.1, Madsen, H.O.2, Ryder, L.P.2,
Svejgaard, A.2, Andersen, P.2, Dickmeiss, E.2, Vindelov, L.L.1 1Alloge-
neic Hematopoietic Cell Transplantation Laboratory, Department of
Hematology, Rigshospitalet, Copenhagen, Denmark; 2Department of
Clinical Immunology, Rigshospitalet, Copenhagen, Denmark.
Graft rejection after hematopoietic cell transplantation (HCT)
with nonmyeloablative conditioning is a rare event and a serious
clinical problem. Manifest (N8) and imminent rejection (N4)
in a cohort of 98 consecutive patients with hematological malig-
nancies were analyzed. The patients were conditioned with ﬂu-
darabine 30 mg/m2 and 2 Gy of total body irradiation and trans-
planted with peripheral blood stem cells. Intervention aiming at
reversing imminent rejection with donor lymphocyte infusion
(DLI) alone or preceded by immunosuppression with pentostatin
was attempted with highly variable results. Chimerism analysis is
the standard method to monitor engraftment and rejection. In the
present report we have evaluated the product of absolute T cell
counts and chimerism, which we have termed absolute chimerism,
for monitoring patients with manifest or imminent rejection. The
results suggest that recipient T cell counts  donor T cell counts
and increasing recipient T cells post-transplant are risk factors for
rejection. Peaks of absolute recipient CD4 and/or CD8 T cell
counts were seen in relation to rejection and peaks of donor CD4
and/or CD8 T cells were seen in connection with acute graft-
versus-host disease. Furthermore absolute chimerism plots in some
cases clearly indicate the time-interval where disappearance of
recipient T cells takes place. These ﬁndings may be of importance
for understanding the cellular mechanisms underlying alloreactiv-
ity. Absolute chimerism plots point to a variable immunosuppres-
sive effect of pentostatin on recipient T cells as explanation for
pentostatin/DLI-failure in reversing rejection. We conclude that
absolute chimerism plots can contribute signiﬁcant new informa-
tion of value for routine monitoring of patients with mixed chi-
merism as well as for research purposes. Following rejection pa-
tients are at risk of dying from infections and progression/relapse
of their malignancy. Retransplantation is feasible and well tolerated
after HCT with nonmyeloablative conditioning. In patients with
imminent graft rejection retransplantation is an attractive alterna-
tive to DLI or immunosuppression/DLI.
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AN IMPROVED METHOD FOR ENGRAFTMENT MONITORING USING
REAL-TIME PCR
McLaughlin, I.J.1, Bost, D.A.1, Mountain, J.L.2, McGinnis, M.D.1,
Krausa, P.1 1Atria Genetics, South San Francisco, CA; 2Department of
Anthropological Sciences and Department of Genetics, Stanford Univer-
sity, Stanford, CA.
The commonly used engraftment monitoring method of short
tandem repeat (STR) ampliﬁcation following allogeneic hemato-
poietic stem cell transplantation (HSCT) is hampered by several
shortcomings affecting sensitivity, accuracy, reproducibility, and
results interpretation. In an effort to provide a better solution, we
have developed a truly quantitative, real-time PCR method. Real-
time PCR technology is ideally suited for this application because
it is highly sensitive and quantitatively much more accurate and
precise than STR analysis. It is not affected by problems inherent
to STR ampliﬁcation and analysis such as plateau bias, preferential
allele ampliﬁcation, and stutter artifacts. With our method,
genomic mixtures are easily resolved, and analysis is straightfor-
ward and automatable. Success and maintenance of allogeneic
HSCT may be enhanced with such an improved engraftment
monitoring method.
We have developed a panel of non-repetitive polymorphic mark-
ers, with representatives on all chromosomes, useful for identifying
differences between recipient and donor pairs. Our statistical anal-
yses given allele frequencies in multiple human populations dem-
onstrate that with relatively high minor allele frequencies, a limited
panel of markers can be assembled which would have high prob-
ability of providing informative markers that could distinguish
HLA-matched individuals. The testing process ﬁrst requires that
the donor and recipient genomic DNA be screened in order to
identify informative markers between the two genomes. Once
deﬁned, these markers are used post-transplant to quantify the
relative percentage of recipient genetic material in the donor back-
ground. Compared to the current STR assays, our method shows
a greater than 100-fold increase in sensitivity with excellent accu-
racy and precision at concentrations as low as 0.01% recipient in a
background of 99.99% donor DNA. Given the reproducibility of
results and ease of data analysis, this approach provides the means
for standardization within a testing lab as well as between testing
centers, which cannot be accomplished with homebrew and off-
label methods such as STR analysis. From a clinical perspective,
improved sensitivity, accuracy, and precision provide the potential
to detect disease relapse or transplant rejection at a much earlier
stage. This information may be useful for improving decisions
related to maintenance treatments such as GVHD prophylaxis
and/or donor lymphocyte infusion.
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CHARACTERISTICS OF TWO CONDITIONING REGIMENS CYCLOPHOS-
PHAMIDE PLUS ANTITHYMOCYTE GLOBULIN VERSUS CYCLOPHOSPH-
AMIDE PLUS BUSULFAN IN ALLOGENEIC STEM CELL TRANSPLANTA-
TION FOR SEVERE APLASTIC ANEMIA
Ommati, L.V.M.1,2, Silva, A.P.1, Silva, L.P.1,2, Faria, J.R.2,
Chaufaille, M.d.L.F.1, Oliveira, J.S.P.1,2 1Universidade Federal de Sa˜o
Paulo - UNIFESP, Sa˜o Paulo, Brazil; 2Hospital Santa Marcelina, Sa˜o
Paulo, Brazil.
We report a retrospective study of the clinical features and
outcome for 32 allogeneic stem cell transplants (AlloSCT) from
HLA-matched sibling donors in severe aplastic anemia condi-
tioned with 200 mg/kg of cyclophosphamide plus 90 mg/kg of
horse antithymocyte globulin (ATG) in 17 patients and 120 mg/kg
of cyclophosphamide plus 12 mg/kg of busulfan (Bu) in 15 patients,
at Hospital Sa˜o Paulo and Hospital Santa Marcelina, from No-
vember 1993 to August 2003. Considering high cost of ATG and
the difﬁculty to obtain it for the majority of our centers, the
objective was to compare clinical variables as age, sex, engraftment,
interval of time from diagnosis to AlloSCT, number infused of
total nuclear cells, previous transfusions, occurrence of acute and
chronic GVHD, infections, acute and late graft rejection and
overall survival, between these two conditioning regimens. We
analyzed the long-term hematopoietic chimerism by FISH, using a
Poster Session II 95
double XY probe, in sex-mismatched pairs, and VNTR, using PCR
with Apo-B, D1S80, vWF and DXS52 primers in all patients.
Mucositis and acute GVHD were more evident in the Bu group.
Late rejection occurred specially in the ATG group. All the others
variables and overall survival were similar between these two con-
ditionings. By FISH evaluation, there were complete chimerism in
8 of 10 patients and there was a case of mixed chimera and another
of autologous reconstitution. VNTR determined chimera in 15 of
17 donor/ recipient pairs (88.2%). Complete chimerism, analyzed
by all primers were seen in 8 of 17 (47%) patients. Mixed chimer-
ism and autologous reconstitution patients, observed by FISH,
were conﬁrmed by VNTR just using D1S80 and vWF primers,
respectively. We conclude that both conditioning regimens were
effective and the analyzed clinical data were comparable between
the groups, however, a larger number of patients need to be studied
in order to establish the best conditioning. The methods for eval-
uation of the chimera are sensitive and informative using VNTR
and FISH methodologies.
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EARLY EXPANSION OF LYMPHOID CELLS PRECEDES MYELOID EN-
GRAFTMENT FOLLOWING HEMATOPOIETIC CELL TRANSPLANTATION
USING TRULY NONMYELOABLATIVE CYCLOPHOSPHAMIDE/FLUDARA-
BINE CONDITIONING
Pandurangadu, A.V.1, Menggang2, Nelson, R.P.3 1Indiana University
School of Medicine, Indianapolis, IN; 2Department of Medicine, Division
of Biostatistics, Indianapolis, IN; 3Department of Medicine, Division of
Hematology/Oncology and the Indiana University Cancer Center, Indi-
anapolis, IN.
Little is known regarding the mechanism of engraftment of
allogeneic cells in humans, partially because there are few cells to
analyze in the early (ﬁrst 2 weeks) post-transplant period. After
myeloablative conditioning, monocytes are the initial donor cells
identiﬁed in recipients’ blood, followed by polymorphonuclear
leukocytes and then lymphocytes.
Forty-nine consecutive patients with hematological malignancies
(median age, 55 years) received PBMCs from a matched related
(MRD) or unrelated (MUD) donor following cyclophosphamide,
60 mg/kg on days –6 and –7 (total dose 120 mg/kg) and ﬂudara-
bine, 25 mg/m2 for 5 consecutive days (day –5 through day –1; total
dose, 125 mg/m2). GVHD prophylaxis consisted of cyclosporine
(n33) or cyclosporine  mycophenolate mofetil (n16). Acyclo-
vir, ﬂuconazole and quinolone prophylaxis were provided and
freshly harvested, non-manipulated PBMCs were infused within 24
hours of collection. One patient with chronic lymphocytic leuke-
mia (CLL) and a pre-transplant lymphocyte count of 150,000/
mm3 (considered an outlier) was removed from the analysis. A
database (Excel®, MS, Redwood, CA) was utilized to record white
blood counts (WBC) obtained from the computerized medical
record; each patient’s total WBC, neutrophil, lymphocyte, and
monocyte percentages were recorded from day –7 to day 30.
Cumulative data were plotted using S-Plus® software (Insightful,
Seattle, WA) and median times to peak percentages were deter-
mined. Patients who received conventional conditioning and sim-
ilar grafts prior to transplantation for hematological malignancies
(AML or MDS) over a similar time period (n46) were studied and
engraftment patterns compared.
The following phenomena were observed after nonmyeloablative
transplantation: (1) no ¨ bump¨ , (increase in the peripheral WBC)
the day following cell infusion; (2) resolution of neutropenia at a
median of 12 days after MUD transplants and 15 days after MRD
transplants (p0.778); (3) median peak lymphocyte, monocyte and
polymorphonuclear percentages occurred 9, 12 and 23 days post-
infusion, respectively.
Early disappearance of infused cells from the circulation and
relative expansion of lymphocytes preceding the emergence of
monocytes and polymorphonuclear cells suggests that relatively
quick engagement of donor cells by the marrow microenvironment
is followed by an immunologically active process after truly non-
myeloablative cyclophosphamide/ﬂudarabine conditioning.
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NON-MYELOABLATIVE CONDITIONING THERAPY WITH FLUDARABINE,
CYCLOPHOSPHAMIDE AND ATG ALLOGENEIC HEMATOPOIETIC STEM
CELL TRANSPLANTATION FROM HLA-IDENTICAL SIBLING DONOR IN
PATIENTS WITH SEVERE APLASIC ANEMIA (SAA)
Pawlowska, A.1, Bolotin, E.1, Falk, P.1, Forman, S.1, LaBossiere, D.1,
Rosenthal, J.1 1City of Hope National Medical and Research Center,
Duarte, CA.
Allogeneic bone marrow transplantation (BMT) from an HLA-
identical sibling is a curative form of therapy for patients with
acquired severe aplastic anemia.
Survival has signiﬁcantly improved over the past 3 decades. The
actuarial risk of rejection has been reduced to about 7%. Improved
results with survival in excess of 90% have been reported. Current
preparative therapies are associated with early and late sequelae
such as acute and chronic graft-versus-host disease (aGvHD or
chGvHD, respectively) and secondary tumors. In two patients (6
years and 11 years old) with SAA, who had an HLA-identical
sibling donor, but could not proceed with myeloablative therapy at
the time of transplant for various reasons (delay in results of
chromosome stability and fragility in one patient and abnormal
pulmonary function in the second), had a non-myeloablative pre-
parative regimen with Fludarabine (30 mg/m2x4 doses) Cyclophos-
phamide (5 mg/kgx4 doses) and rabbit ATG (1.5 mg/kgx4 doses)
followed by an unmanipulated allogeneic BMT. Graft versus host
disease prophylaxis consisted of Cyclosporine from day -1 and
Methotrexate 15 mg/m2 on day1 and 10 mg/m2 on days3,6,
11 after transplant. Myeloid engraftment occurred on day 15
and day 28. The time to a platelet count 20,000 unsupported
was 11 days and 29 days. No transplant-related toxicities,
including mucositis or alopecia, were recorded. There were no
signs for aGvHD or chGvHD. The patients continue with full
donor chimerism 31 months and 6 months post transplant, respec-
tively. This data suggests that a non-myeloablative, immunosup-
pressive regimen is sufﬁcient to provide a stable engraftment in
patients with SAA. This approach may be associated with de-
creased transplant-related short- and long-term toxicities. A larger
study is needed to fully evaluate the outcome and toxicities proﬁle
associated with this conditioning.
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INFLUENCE OF INTERLEUKIN-6 (IL-6) GENE POLYMORPHISM ON THE
OUTCOME OF PATIENTS UNDERGOING ALLOGENEIC STEM CELL
TRANSPLANTATION
Raida, L.1, Faber, E.1, Mrazek, F.2, Indrak, K.1, Petrek, M.2,
Zapletalova, J.3, Ambruzova, Z.2, Kriegova, E.2, Onderkova, J.2 1He-
mato-Oncology Dpt., University Hospital, Olomouc, Czech Republic;
2Dpt. of Biophysics, Medical School of Palacky University, Olomouc,
Czech Republic.
BACKGROUND: IL-6 is an important mediator of inﬂamma-
tion and its production depends on the functional IL-6 gene
polymorphism (IL-6-174*G/C). Allele G expression is associated
with higher IL-6 production. The polymorphism of recipient
and/or donor might inﬂuence immunological reactions after allo-
geneic stem cell transplantation (SCT), particularly graft vs. host
disease (GvHD) and graft vs. tumor (GvT) one.
AIM OF STUDY: To assess the inﬂuence of recipient/donor
functional IL-6 gene polymorphism on the development of acute/
chronic GvHD, tumor relapse and mortality.
PATIENTS AND METHODS: 56 patients were allografted
from HLA-identical related donor. 54 recipients (96%) underwent
the procedure because of incurable hematological malignancy and
33 ones (59%) after reduced intensity conditioning (RIC). IL-6-
174* genotyping of recipients/donors was provided by the use of
polymerase chain reaction with sequential speciﬁc primers (PCR-
SSP). The inﬂuence of GvHD development, tumor relapse and
mortality on the IL-6-174*G/C allele manifestation in recipients/
donors was assessed by the methods of univariate as well as mul-
tivariate statistical analysis.
RESULTS: Statistical analysis did not conﬁrm the signiﬁcant
inﬂuence of functional IL-6 gene polymorphism of recipients/
Poster Session II96
